Xintela AB (publ) Share Price Nasdaq Stockholm
Equities
SE0007756903
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | 78K 7.19K 574K | Capitalization | 148M 13.64M 1.09B |
---|---|---|---|---|---|
Net income 2022 | -66M -6.09M -486M | Net income 2023 | -54M -4.98M -398M | EV / Sales 2022 | - |
Net cash position 2022 | 8.34M 769K 61.44M | Net cash position 2023 | 7.81M 720K 57.51M | EV / Sales 2023 | 1,797 x |
P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-2.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 31.28% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 67 | 31/12/08 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 31/12/12 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 28/02/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 31/12/20 |
Chairman | 67 | 31/12/10 | |
Director/Board Member | 64 | 31/12/21 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |